Tofenacin

Tofenacin
Clinical data
Trade names	Elamol, Tofacine, Tofalin
Other names	tofenacin hydrochloride (USAN US)
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name N-methyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine;
CAS Number	15301-93-6 ; 10488-36-5 (HCl);
PubChem CID	25315;
ChemSpider	23647;
UNII	C4A112M10H;
ECHA InfoCard	100.035.746
Chemical and physical data
Formula	C17H21NO
Molar mass	255.361 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O(CCNC)C(c1ccccc1)c2ccccc2C;
	InChI InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)17(19-13-12-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3; Key:PNYKGCPSFKLFKA-UHFFFAOYSA-N;

Tofenacin is an antidepressant drug with a tricyclic-like structure which was developed and marketed in the United Kingdom and Italy in 1971 and 1981, respectively, by Brocades-Stheeman & Pharmacia (now part of Astellas Pharma).^[1]^[2]^[3] It acts as a serotonin-norepinephrine reuptake inhibitor,^[4] and based on its close relation to orphenadrine, may also possess anticholinergic and antihistamine properties. Tofenacin is also the major active metabolite of orphenadrine and likely plays a role in its beneficial effects against depressive symptoms seen in Parkinson's disease patients.^[5]^[6]

References[]

^ Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 1041. ISBN 978-3-88763-075-1. Retrieved 19 May 2012.
^ J. Buckingham (1996). Dictionary of organic compounds: Chemical Abstracts Service registry number index. CRC Press. p. 6074. ISBN 978-0-412-54090-5. Retrieved 19 May 2012.
^ Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. 2013-01-15. p. 3268. ISBN 978-0-8155-1526-5. Retrieved 19 May 2012.
^ Gwynn Pennant Ellis; Geoffrey Buckle West (1 January 1978). Progress in Medicinal Chemistry. Elsevier. p. 284. ISBN 978-0-7204-0655-9. Retrieved 19 May 2012.
^ Capstick N, Pudney H (1976). "A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy". The Journal of International Medical Research. 4 (6): 435–40. doi:10.1177/030006057600400610. PMID 800383. S2CID 40083513.
^ Altamura AC, Mauri MC, De Novellis F, Percudani M, Vampini V (November 1989). "Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine". Pharmacopsychiatry. 22 (6): 246–9. doi:10.1055/s-2007-1014608. PMID 2616635.

This drug article relating to the nervous system is a stub. You can help Wikipedia by .

[Index_Nominum_2000:_International_Drug_Directory-1] Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 1041. ISBN 978-3-88763-075-1. Retrieved 19 May 2012.

[Buckingham1996-2] J. Buckingham (1996). Dictionary of organic compounds: Chemical Abstracts Service registry number index. CRC Press. p. 6074. ISBN 978-0-412-54090-5. Retrieved 19 May 2012.

[Pharmaceutical_Manufacturing_Encyclopedia,_3rd_Edition-3] Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. 2013-01-15. p. 3268. ISBN 978-0-8155-1526-5. Retrieved 19 May 2012.

[EllisWest1978-4] Gwynn Pennant Ellis; Geoffrey Buckle West (1 January 1978). Progress in Medicinal Chemistry. Elsevier. p. 284. ISBN 978-0-7204-0655-9. Retrieved 19 May 2012.

[pmid800383-5] Capstick N, Pudney H (1976). "A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy". The Journal of International Medical Research. 4 (6): 435–40. doi:10.1177/030006057600400610. PMID 800383. S2CID 40083513.

[pmid2616635-6] Altamura AC, Mauri MC, De Novellis F, Percudani M, Vampini V (November 1989). "Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine". Pharmacopsychiatry. 22 (6): 246–9. doi:10.1055/s-2007-1014608. PMID 2616635.

[1]

[2]

[3]

[4]

[5]

[6]

Tofenacin

See also[]

References[]